Use of inhibitors of IL-1 and TNF antagonists, partly in combination with recombinant erythropoietins for the treatment of anemia

摘要

lnhibidor IL-1 receptor agonist of erythropoietin (EPO) for use in a method of treating anemia in a mammal, comprising administering to the mammal a therapeutically effective amount of said inhibitor and agonist, wherein the inhibitor of IL -1 is IL-lra protein or a derivative or variant thereof with a sequence homology of at least 90%, which inhibits the activation of cellular receptors by IL-1; and wherein the receptor agonist EPO is EPO, epoetin alfa, darbepoetin alfa, one antiagonista receptor antibody EPO or a derivative or variant thereof with a sequence homology of at least 90%, which produces the activation of EPO receptor.